What Does ClearPoint Neuro (CLPT) Do? — Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters at a Glance
ClearPoint Neuro (CLPT) is a US medical-device company that provides an MRI-guided neurosurgical platform and drug-delivery services for biopharmaceutical partners. The stock outlook is defined by growth in neurosurgery disposables and biopharma drug-delivery revenue, supported by a growing roster of clinical-trial partnerships.
Subscribe🏢 What kind of company is ClearPoint Neuro?
ClearPoint Neuro (CLPT) is a US-headquartered medical-device company that develops and supplies an MRI-guided precision neurosurgery platform. Its core asset is a navigation technology that provides real-time guidance for deep-brain procedure trajectories based on MRI imaging.
The company operates a neurosurgery navigation system along with single-use disposables, as well as drug-delivery services for biopharmaceutical companies running central nervous system (CNS) clinical trials. It holds a leading position in the niche field of MRI-guided procedures.
💰 How does ClearPoint Neuro make money?
| Business Segment | Revenue Mix | Description |
|---|---|---|
| Neurosurgery Disposables | Core | Single-use disposables and navigation consumables for brain procedures |
| Biopharma & Drug Delivery | Key Growth Driver | Drug-delivery services for biopharma clinical trials of new drugs |
| Capital Equipment | Diversification Arm | Installation of MRI-guided navigation systems |
| Neuro Critical Care | New Expansion | Neuro critical care segment added through a recent acquisition |
Annual revenue has continued on a stable trajectory, with the neurosurgery disposables and biopharma drug-delivery segments jointly driving the top line. Recurring disposable revenue tied to procedure volumes adds stability, while clinical-trial collaborations with multiple biopharma partners serve as the central engine for drug-delivery service revenue. Capital-equipment installations create a virtuous cycle that generates downstream disposable revenue, and margins show variability consistent with a growth-investment phase.
ClearPoint Neuro Market Cap and Company Scale
Market capitalization stands at $418.5M, and headcount is approximately 172 people.
As a small-cap medical-device company focused on the niche of MRI-guided neurosurgery, it differs significantly in scale from large players such as MDT, SYK, and ISRG that dominate the broader neurosurgery market. Given its growth-stage profile, the company tends to allocate resources toward R&D and partnership expansion rather than capital return.
📈 ClearPoint Neuro Outlook and Price Action
1-Year Price Performance
Analyst Consensus
52-Week Price RangeThe expansion of CNS drug development and the growing roster of biopharma partnerships are the key medium- to long-term growth drivers. Multiple clinical-trial collaborations and secured regulatory expedited-review pathways enhance visibility for drug-delivery service revenue, while recurring disposable revenue from the installed navigation base adds stability. In the near term, profitability volatility stemming from growth investments and exposure to clinical timelines and partner drug outcomes can act as swing factors, and the broad resources of large competitors such as MDT and SYK remain a competitive pressure point.
- Expansion of biopharma partnerships and drug-delivery services
- Growth in recurring neurosurgery disposable revenue
- New indication expansion via regulatory expedited-review pathways
⚔️ ClearPoint Neuro Key Strengths and Risks
First-mover position in the MRI-guided procedure niche and recurring revenue anchored by biopharma partnerships are strengths, while small scale and exposure to large competitors are the core risks.
Key Strengths
Key Risks
🔄 ClearPoint Neuro Competitors and Related (Beneficiary) Stocks
Within a similar size band, small-cap medical-device peers include spinal-implant player SIBN, surgical-robotics company PRCT, and neurotherapy firm PSTV, which together form the small-cap medical-device cohort. Related names include large-cap leaders across the broader neurosurgery and medical-device markets, such as broad-based medical-device giant MDT, surgical-equipment leader SYK, and robotic-surgery leader ISRG. These are closer to much larger adjacent threats, while CLPT remains focused on the MRI-guided niche.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 SIBN | SI-BONE Inc | $18.38 | +0.4% | $823.8M | - | 4.5 | -8.3% | - |
 PRCT | Procept BioRobotics Corp | $20.37 | +1.5% | $1.2B | - | 3.4 | -30.24% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| MDT | Medtronic Plc | $90.96 | -0.7% | $116.4B | 22.4 | 2.3 | 10.66% | 3.18% |
| SYK | Stryker Corp | $275.56 | +2.1% | $105.7B | 28.6 | 4.4 | 16.51% | 1.28% |
| ISRG | Intuitive Surgical Inc | $369.68 | +2.6% | $130.6B | 42.4 | 7.2 | 17.43% | - |
✅ ClearPoint Neuro Investor Checklist
Key points to review when evaluating ClearPoint Neuro. Growth in biopharma partnerships and the trajectory of drug-delivery service revenue, along with the growth pace of recurring neurosurgery disposable revenue, serve as the central short- and medium-term variables.
| Check Item | What to Verify | Current Status |
|---|---|---|
| 🧪 Partnership Expansion | Number of biopharma new-drug collaborations and drug-delivery revenue trends | Expanding |
| 📈 Disposable Growth | Growth pace of single-use neurosurgery disposable revenue | Growth Phase |
| 💵 Profitability | Balance between growth investment and margins | Volatile Phase |
| ⚔️ Competitive Landscape | Niche defensiveness versus large medical-device players | Monitor |
Given its small-cap profile, the stock is sensitive to revenue volatility and profitability pressure, and drug-delivery revenue can hinge on the clinical outcomes of partner programs. The resource advantages of large competitors such as MDT and SYK, together with cash-flow variability tied to growth investments, are also near-term risk factors.
ClearPoint Neuro is a growth-stage medical-device name that has staked out a niche in MRI-guided neurosurgery and biopharma drug delivery. Partnership expansion and recurring disposable revenue growth are the key variables to monitor. Given the elevated volatility typical of a small-cap stock, a phased buying approach with a long-term perspective is recommended.
Subscribe Today's 5 AI picks, all free